A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Elotuzumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Dec 2017 Planned End Date changed from 31 Mar 2026 to 28 Feb 2026.
- 01 Dec 2017 Planned primary completion date changed from 30 Jun 2021 to 31 May 2021.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.